Key Highlights

  • The Federal Trade Commission sent information demands to customers and rivals of Cencora's MWI Animal Health unit and Covetrus, according to a Bloomberg report citing people familiar with the matter.
  • The scrutiny concerns a proposed 3.5 billion dollar enterprise value deal combining MWI Animal Health with Covetrus, announced in February.
  • The FTC's requests reportedly seek details on how the deal would affect availability of veterinary products and practice-management software used by clinics.
  • Cencora, Covetrus and the FTC did not immediately respond to requests for comment on the report.

Regulatory Attention Follows a February Deal Announcement

The Federal Trade Commission has sent information demands to customers and rivals of Covetrus and MWI Animal Health, according to a News report citing people familiar with the matter, signaling closer antitrust scrutiny of a proposed merger combining two leading national suppliers of veterinary products. The requests reportedly seek details on how the transaction would affect the availability of veterinary products as well as practice-management software, tools clinics rely on to manage patient records, prescriptions and payments.

The scrutiny centers on a deal Cencora (NYSE:COR) and Covetrus announced in February, under which MWI Animal Health, currently owned by Cencora, would merge with Covetrus to create a combined animal health platform. The transaction values MWI at an enterprise value of 3.5 billion dollars, with Cencora set to receive 1.25 billion dollars in upfront cash proceeds, 800 million dollars in preferred equity, and a non-controlling 34.3% common equity stake in the combined company.

Deal Structure Reflects Cencora's Broader Strategic Refocus

Cencora's decision to divest MWI Animal Health reflects the company's stated strategy of sharpening its focus on core drug distribution operations while divesting non-core businesses. Cencora's chief executive said at the time of the original announcement that the transaction would position MWI for success with a partner strategically dedicated to animal health, while allowing Cencora to reinvest in its primary growth priorities within pharmaceutical distribution.

Covetrus's chief executive framed the combination as an opportunity to expand the company's ability to serve veterinary practices by integrating MWI's distribution capabilities with Covetrus's existing technology-enabled solutions, with the stated goal of improving affordability and access across the animal health ecosystem. The transaction remains subject to customary closing conditions, including required regulatory approvals, a process now apparently facing more detailed examination than a standard review might typically involve.

Antitrust Focus on Distribution and Software Overlap Raises Deal Risk

The FTC's specific interest in both physical veterinary product distribution and practice-management software suggests regulators are examining potential competitive overlap across multiple business lines simultaneously, rather than scrutinizing a single, narrowly defined market. This dual focus could complicate the review process if regulators identify concerns spanning both the distribution and technology components of the combined company's operations.

Cencora's reaffirmed fiscal 2026 guidance, issued at the time of the original deal announcement, did not contemplate the transaction closing within that fiscal year, which ends September 30, 2026, suggesting the companies themselves anticipated a review process extending beyond the near term even before this reported regulatory attention became public. Should the FTC ultimately raise substantive competitive concerns, the deal could face extended timelines, required divestitures, or other conditions before regulatory approval is granted, none of which have been confirmed based on currently available information.

Conclusion

Reported FTC scrutiny of the Cencora-Covetrus animal health merger introduces meaningful uncertainty into a deal that had otherwise proceeded through standard announcement and advisory processes since February. The regulatory focus on both product distribution and software competition suggests a thorough review examining multiple dimensions of potential market impact within the veterinary health sector. Whether this scrutiny ultimately results in required deal modifications or an extended approval timeline is likely to become clearer as the FTC's review process continues and the companies respond to information requests.